September 28th 2025, 2:00pm
By Samantha Darling
I faced breast cancer and unexpected body changes with resilience and humor, learning to adapt and find strength in the process.
September 27th 2025, 6:00pm
By Dr. Alexander Spira
Dr. Alexander Spira explained the difference between a clinical trial and a real-world study in a CURE interview for patients with lung cancer.
September 27th 2025, 2:00pm
By Ryan Scott
Cancer during pregnancy is rare but increasingly recognized as maternal age rises and non-invasive prenatal testing becomes more common.
September 26th 2025, 8:00pm
By Dr. Geoffrey Liu
Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.
September 26th 2025, 7:00pm
By Alex Biese
Urothelial carcinoma, the most common type of bladder cancer, is explained from diagnosis to treatment.
September 26th 2025, 5:00pm
By Martha Carlson
As a metastatic breast cancer patient, I want to control what I can, including my diet and exercise.
September 26th 2025, 4:00pm
By Gina Mauro
This in-depth guide offers a clear look at papillary thyroid cancer, from initial diagnosis and treatment options to long-term prognosis and living well after treatment.
September 26th 2025, 3:00pm
Utidelone, previously received orphan drug designation from the FDA for the treatment of breast cancer brain metastases and gastric cancer.
September 26th 2025, 1:00pm
By Spencer Feldman
Adrenal cancer is rare, but surgery, medicines, chemotherapy and clinical trials can help patients based on stage, spread and overall health.
September 25th 2025, 9:00pm
By Dr. Lorenzo Belluomini
Targeted therapies have changed non-small cell lung cancer care, but new side effects, like weight gain, are emerging, says Dr. Lorenzo Belluomini.
Lymphoma is a treatable cancer of the immune system; early diagnosis and personalized treatment with chemo and radiation often lead to a cure.
September 25th 2025, 8:00pm
By Dr. Jacob Sands
Dr. Jacob A. Sands shares how patients with lung cancer can interpret clinical trial results and how these findings translate to treatment decisions.
September 25th 2025, 6:38pm
Inluriyo, an oral therapy for ER+, HER2– metastatic breast cancer with ESR1 mutations, offers a new treatment option after prior endocrine therapy.
September 25th 2025, 5:00pm
By Georgia Hurst
Tending my garden and observing nature teaches me resilience, presence, and growth, helping me carry joy and sorrow while living with Lynch syndrome.
September 25th 2025, 4:00pm
Women with a history of cervical cancer are nearly twice as likely to develop anal cancer as members of the general population, according to researchers.
Finding Credible Voices in the Lynch Syndrome Community
Understanding Your Stage 2 Lymphoma Diagnosis
FDA Approves Revuforj for R/R NPM1-Mutant AML
How Does FDA-Approved Blenrep Treat Multiple Myeloma?